Triple W develops novel incontinence wearable device
Triple W, a San Diego- based startup company, on Monday announced the development of the first connected incontinence wearable device that can track the progression of bladder movements using non-invasive ultrasonic sensors.
“Health services globally are struggling with the burden of growing and aging populations and continue to put more emphasis on patients and caregivers to monitor their own well-being,” Atsushi Nakanishi, president and CEO Triple W, said. “I believe the potential for a device like DFree in the U.S. is vast and we are looking forward to making the product available later this year. Our mission is to help people with incontinence regain dignity and confidence so that they can live their life to the fullest.”
The device will help elderly and disabled people who suffer from incontinence by notifying them when they will need to go to the bathroom. As a result, users no longer have to worry about accidents and can often forgo the embarrassment of wearing diapers.
The device is placed on the lower abdomen and uses ultrasonic sensors to monitor the change in bladder size. The data collected is then sent to a server where it is analyzed using a patented algorithm. The notification goes to a smartphone or tablet used by the patient, nurse or caregivers, and informs them when it is necessary to go to the bathroom.
Triple W has won numerous innovation awards with the most recent one being the Pitch Innovation Prize by AgeingFit, an organization accelerating innovation for the senior market. Triple W will also be exhibiting the DFree at Medtrade, an international trade show and conference for the home healthcare industry, held in Las Vegas this month.
The company is currently exploring new partnership opportunities with U.S. retailers and distributors, as well as collaborative opportunities with other U.S. healthcare companies.
Perrigo gains FDA approval for Mucinex DM
Perrigo on Tuesday announced it has received final approval from the U.S. Food & Drug administration for the store brand OTC equivalent of Mucinex DM Maximum Strength (guaifenesin and dextromethorphan hydrobromide extended-release tablets, 1200 mg/60 mg).
“This final approval and upcoming launch is an important accomplishment for our OTC business,” Jeff Needham, executive vice president and president, Consumer Healthcare Americas, for Perrigo, said. “Key product launches like Perrigo’s store brand equivalent of Mucinex® DM Maximum Strength provide our customers and consumers with high quality, value alternatives in important treatment categories.”
Mucinex DM Maximum Strength is indicated to control coughs and to break up mucus, making coughs more productive. Retail sales of the cough-cold product for the last 12 months were approximately $128 million as measured by IRI, Perrigo reported.
The company is finalizing plans to launch Perrigo’s wholly owned store brand equivalent of Mucinex DM Maximum Strength for the 2018 cough-cold season.
This product will be packaged and marketed as a retailer own brand and will provide consumers with a value alternative to Mucinex DM Maximum Strength.
Payfone and higi showcase upgraded digital experience
Payfone, a leading digital identity authentication network, and higi, a population health enablement company, on Monday unveiled a “Future of Healthcare Engagement Technology” experience at the Healthcare Information and Management Systems Society Conference in Las Vegas. The interactive demonstration showcased innovative capabilities from Payfone and higi that enable an elevated digital engagement experience for scalable population health solutions while protecting protected health information.
“We take pride in empowering enterprises across all sectors to deliver seamless, instant and secure experiences for their customers,” Rodger Desai, CEO of Payfone, said. “For the healthcare industry, that means allowing consumers to safely and conveniently access services like higi’s that can improve their health, while enforcing the highest levels of protected health information security. We are excited that our partnership with higi will allow us to use our advanced technology to better the lives and health of Americans.”
By rolling out Payfone’s secure passive identity authentication technology, which is also used by six of the top 10 banks in the United States, across higi’s 11,000 FDA-cleared self-screening kiosks across the U.S., higi will enable consumers to experience an easier way to measure and track their health data and share it with healthcare organizations and pharmacy retailers for immediate recommendations at a point of care.
Through the Payfone integration, individuals can use their cell phone to log in to a higi health station and initiate digital messaging from their health network.
“As consumers look for easier and more secure ways to manage their health data, we are thrilled to partner with Payfone and further our commitment to empowering consumers to be their healthiest while making it easier along the way,” Jeff Bennett, CEO of higi, said. “With the combined Payfone and higi capabilities, healthcare organizations can leverage a consumer-centric model to deploy scalable population health programs over a safe, secure and real-time digital platform.”